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RESEARCH NOTE
Knowledge is power: general practitioners 
prescribing of new oral anticoagulants in Ireland
A. Murphy1* , A. Kirby1 and C. Bradley2
Abstract 
Objective: New oral anticoagulants (NOACs) aim to overcome warfarin’s shortcomings, however their pharmacoki-
netic characteristics make prescribing complex. Thus it is imperative that general practitioners (GPs) are aware of 
specific treatments so as to maximise their benefits and minimise their pitfalls. This study explores GPs attitudes and 
experiences with prescribing NOACs in Ireland where, despite clear national prescribing guidelines advocating warfa-
rin as first line therapy, the number of patients being prescribed NOACs for the first time is growing.
Results: Using primary data collected from GPs in Ireland the factors influencing the likelihood of a GP initiating 
a prescription for a NOAC are determined using a probit model. Results indicate 46% of the sample initiated NOAC 
prescriptions and GP practice size is a significant factor influencing this. Analysis revealed no difference regarding the 
sources of information considered important amongst GPs when prescribing new drugs. However, there were differ-
ences in which factors were considered important when prescribing anticoagulants between initiating and non-initi-
ating NOAC prescribers. The results of this study suggest better utilisation of existing information and education tools 
for GPs prescribing NOACs and managing NOAC patients is imperative, to ensure the right anticoagulant is prescribed 
for the right patient at the right time.
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Introduction
Atrial fibrillation (AF) is an abnormal heart rhythm. 
Owing to risk of thromboembolism, patients with AF 
have a five-fold increase in risk of having a stroke [1] and 
higher mortality and recurrence [2]. To prevent stroke 
and thromboembolism AF patients are typically admin-
istered an anticoagulant. Warfarin, the original antico-
agulant, has been prescribed for decades worldwide [3]. 
Recently four new anticoagulants acquired European 
Medicines Agency and Food and Drug Administra-
tion approval: dabigatran, rivaroxaban, apixaban and 
edoxaban. They are collectively referred to as new oral 
anticoagulants (NOACs), and more recently direct oral 
anticoagulants (DOACs).
Despite its dominance, those on warfarin are at risk of 
bleeding, consequently extensive monitoring is required 
owing to its narrow therapeutic range, which is expensive 
and time consuming [4]. NOACs have broadly similar 
efficacy and safety compared with warfarin and are thus 
emerging as alternatives for the prevention of stroke and 
embolic events in AF patients [5]. Nevertheless, there are 
pharmacology differences amongst NOACs, as well as 
differences in the trial designs and outcomes on which 
their potential is based. These result in challenging clini-
cal issues [5–7] which need to be understood and consid-
ered by prescribers. Furthermore, NOACs are expensive 
so to achieve value for money it is imperative that they 
are prescribed appropriately.
NOACs have been adopted rapidly in the US and other 
jurisdictions, but some health authorities have been 
more cautious. For example, in Ireland even though each 
NOAC is considered cost effective, warfarin remains the 
preferred anticoagulant for stroke prevention amongst 
non-valvular AF patients, followed by apixaban [8]. Yet 
NOACs are increasingly prescribed for AF patients. 
Between January 2013 and March 2014, 8399 patients 
were prescribed NOACs for the first time [8] and in 2014 
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expenditure on NOACs represented 88% of total annual 
spend on anticoagulants [9].
The range of influences on NOAC prescribing is 
diverse. Huang et al. [10] found dabigatran prescribing is 
influenced by cost, safety and effectiveness of dabigatran; 
patients’ previous exposure; adherence and experience 
with warfarin; as well as patient preferences [10]. Further 
studies are needed to investigate NOAC prescribing pat-
terns [11].
This study examines the factors that influence general 
practitioners (GPs) when initiating NOAC prescribing 
in Ireland. While a multi-disciplinary approach is advo-
cated to prescribing NOACs, the GP is often patients’ 
first point of contact. Consequently, local leadership and 
expert champions amongst GPs are advocated [12, 13].
Ireland was chosen as a case study for this analysis 
owing to the relatively conservative approach to pre-
scribing NOACs being advocated by authorities. Fur-
thermore, as Ireland features a mix of public and private 
patients it has features of both the social insurance and 
private health care systems. In Ireland the state pays for 
approximately 80% of all medicines through general taxa-
tion. The remaining 20% is funded through out of pocket 
payments. Through means-tested schemes GP visits and 
drugs are paid for or subsidized in the community. In 
addition, for patients ineligible for existing schemes there 
is a separate NOAC reimbursement scheme [14]. Thus 
there is little incentive for public patients to take into 
account price differences and no income incentive on the 
physicians’ choice of drug.
Main text
Methods
A dedicated postal survey was designed, piloted and 
disseminated to Irish GPs in November 2015. Ethi-
cal approval was acquired from the University’s Social 
Research Ethics Committee. There are approximately 
2500 practicing GPs in Ireland (combination of private 
and public practice) [15]. As a current comprehensive 
list of GPs was not available as a sampling frame, the tel-
ephone directory was used to compile a listing of over 
1422 GPs (as per Bourke and Bradley [16]). Excluding 
incomplete surveys the sample size was 221 (15%).
A probit model was employed to determine the factors 
influencing the likelihood of a GP initiating a prescrip-
tion for a NOAC (StataCorp LP). This accommodated a 
binary dependent variable with a separation between GPs 
who initiated prescribing of new oral anticoagulants and 
GPs who did not. Here the dependent Y represents an 
initiating prescriber of NOACs/non-initiating prescriber 
of NOACs. Included is a vector of regressors XT which 
influences the outcome variable (includes gender, age, 
number employed in practice, location of the practice, 
services provided at the practice (anticoagulation, diet, 
counsellor and physiotherapy clinics), dispensing service 
and if the practice is a GP training practice).
where Pr denotes the probability, φ is the cumulative dis-
tribution function of the standard normal distribution. 
The parameters that are included in β are estimated by 
maximum likelihood. Marginal Effects were also esti-
mated and presented.
Results
Important factors influencing initial prescribers of NOACs
All respondents had patients currently prescribed 
an anticoagulant for AF. 70% of GPs were male, aged 
53 years on average. Over half the respondents are based 
in GP practices in the southern region of Ireland (Mun-
ster) and 61% in a city or large town. With regard to 
practice size, the average number of public patients per 
practice is 1681 and private patients is 2037. Most prac-
tices employ a mix of full and part time staff, with five 
staff members on average. 36% reported having antico-
agulation clinics and 10% reported having other clinics. 
Table 1 presents the summary statistics.
The survey differentiated between GPs who had, them-
selves, initiated NOAC prescribing (46%) and those who 
had not (54%). (The latter do prescribe NOACs but only 
when prescribing has been initiated by another clinician).
Amongst the full sample, hospital consultants (92%), 
other GPs (86%), conferences (83%) and journals (79%) 
were ranked as important influences for GPs when pre-
scribing new drugs. Pharmaceutical representatives 
(67%) and pharmaceutical representatives at events (54%) 
and the internet (50%) were ranked as not important 
(aggregate of responses 1 or 2). The order of these rank-
ings was the same amongst initiating prescribers.
Respondents were also asked to rank by importance the 
factors that influence their NOAC prescribing decision 
for patients with AF (Fig. 1). Over 90% of all respondents 
indicated that drug interactions, previous experience 
with the drug, efficacy, monitoring requirements, patient 
non-compliance, other co-morbidities and hepatic 
impairment were important factors to consider when 
prescribing NOACs. Renal impairment was only ranked 
as important by 84% of the sample, cost of the medica-
tion by 75% of the total sample and socio-economic fac-
tors were ranked as important by 59% of the sample.
Comparing factor rankings between initiating pre-
scribers of NOACs (n = 101) and non-initiating pre-
scribers (n = 120) there are few differences. Over 90% 
of initiating prescribers ranked drug interactions, previ-
ous experience, efficacy, monitoring requirements, other 
Pr (Y = 1|X) = φ(XTβ)
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co-morbidities, patient non-compliance, and hepatic 
impairment as important. Over 80% ranked, adminis-
trative burden, patient request, side effects and renal 
impairment as important. However, only 82% of initiat-
ing prescribers ranked renal impairment as important 
compared with 84% of the full sample. In the full sample, 
prescribers in 15 practices ranked all three factors (i.e., 
renal impairment, hepatic impairment and other co-mor-
bidities) as not important (i.e., ranked all three factors 1 
or 2). As these account for approximately 95 patients on 
NOACs this is cause for concern. Meanwhile amongst 
non-initiating prescribers only 87% ranked monitor-
ing requirements as important, while only 88% ranked 
patient non-compliance as important. Interestingly, more 
non-initiating prescribers (76% versus 69%) ranked local 
and national guidelines as important.
GP practice characteristics influencing prescribers who 
initiate NOAC prescriptions
The probit model was used to determine the factors 
influencing the probability of a GP initiating a NOAC 
prescription. The dependent variable was initiating or 
non-initiating prescribers of NOACs. Practice size was 
measured by the number of employees in the model and 
the location of the practice was measured using a dummy 
variable for urban and rural areas. Correlation between 
age and years practicing as a GP was expected and con-
firmed (0.88) so to avoid multicollinearity only age was 
included. The marginal effect was estimated at the mean. 
The probit results revealed that as practice size increased 
GPs were more likely to initiate NOAC prescriptions 
holding all other variables at the mean (Table  2). No 
other variables were found to be statistically significant.
Discussion
While some of the concerns around NOACs are being 
resolved (increased monitoring and emergence of anti-
dotes etc.) others persist owing to their pharmacokinetic 
and pharmacodynamic characteristics. As NOAC pre-
scribing continues to grow their successful use relies on 
prescribers and those managing NOAC patients’ care 
understanding these considerations. This requires educa-
tion and guidance to ensure; proper clinical management 
for monitoring [6, 17]; that the advantages and limita-
tions of NOACs for prescribers are recognised [18]; that 
the management of complications and adverse events are 
Table 1 Summary statistics: GP practices in Ireland
Provinces aggregate to 214 due to non-response. Size of practice, No. of GMS and Private patients have 5, 6 and 15 missing values respectively
Variable name Full sample (N = 221) Initiating prescribers (N = 101) Non initiating 
prescribers 
(N = 120)
Mean (SD) Mean (SD) Mean (SD)
Age 53 (10.23) 52 (9.71) 53 (10.66)
No. of GMS 1681 (1380) 1972 (1439) 1427 (1279)
No. of private 2037 (2205) 2472 (2583) 1658 (1738)
Size of the practice 3616 (3148) 4345 (3662) 2988 (2476)
No. of employees 5 (4) 5 (4) 5 (4)
Freq (%) Freq (%) Freq (%)
Males 154 (70) 74 (73) 80 (67)
Munster 108 (49) 53 (52) 55 (46)
Leinster 63 (29) 25 (25) 38 (32)
Connaght 33 (15) 17 (17) 16 (13)
Ulster 10 (5) 6 (6) 8 (7)
City 69 (31) 24 (24) 45 (37)
Large Town (3000–10,000) 67 (30) 34 (34) 33 (27)
Small town (800–3000) 45 (20) 29 (29) 16 (13)
Village (< 800) 28 (14) 10 (10) 18 (15)
Rural 12 (5) 4 (3) 8 (7)
Anticoagulation clinic 7 (3) 4 (4) 3 (2)
Dispensing clinic 15 (7) 8 (8) 7(6)
Physiotherapy clinic 44 (2) 17 (17) 27 (22)
Diet clinic 40 (18) 17 (17) 23 (17)
GP training practice 73 (33) 37 (37) 36 (30)
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known and appreciated [6, 19] and that physician knowl-
edge and confidence is increased, specifically on the 
pharmacokinetic and pharmacodynamic characteristics 
of the agents [19].
The success of NOAC prescribing also requires integra-
tion between services, particularly between hospital con-
sultants and GPs who are caring for NOAC patients. The 
survey results reported indicate that GPs are cognisant of 
this (hospital consultants are acknowledged an important 
source of information). Furthermore, the probit model 
results indicate that practice size is a positive influence 
on being an initial prescriber. This result could suggest 
that as a practice grows in size that there is more oppor-
tunity to share information from different sources.
With regard to important factors to consider when 
prescribing anticoagulants some knowledge gaps exist 
between prescribers and non-prescribers. For example, 
a greater share of those who are prescribing NOACs 
acknowledged patient non-compliance and the need for 
some type of monitoring. Given the differences in half-
life between different NOACs these are important con-
siderations when treating patients prescribed NOACs or 
when prescribing NOACs for the first time. Furthermore, 
about 16% of the full sample and 18% of GPs initiating 
prescribing considered renal impairment as not-impor-
tant; while 6% of GPs in the full sample and 4% of ini-
tiating prescribers considered hepatic impairment as not 
important when prescribing NOACs. Given the empha-
sis placed on these two factors by the European Heart 
Rhythm Association [20] and Irish College of General 
Practitioners [21] guidelines this is worrying. It suggests 
better dissemination of and greater emphasis on existing 
Fig. 1 Important factors influencing NOAC prescribing. Note respondents were asked to rank the importance of each factors from 1 to 5, where 1 
was not important and 5 was very important. Important here is the aggregate of responses equal to 3, 4 and 5
Table 2 Probit results for initial prescribers
*5% level of significance
Variables dy/dx SE
Male 0.096 0.074
Age − 0.001 0.003
No. of employees 0.024* 0.012
Urban 0.100 0.092
Anticoagulation clinic 0.097 0.256
Dispensing clinic 0.079 0.180
GP training practice 0.048 0.075
Physiotherapy clinic − 0.098 0.092
Diet clinic − 0.086 0.096
Counsellor clinic 0.026 0.084
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information tools, such as the “Anticoagulation Prescrib-
ing Tips” guide [8], to inform prescribers as suggested 
in the literature [6, 18, 19]. Moreover, this suggests that 
experience with prescribing warfarin is not a substitu-
tion for knowledge and education about NOACs. Also, 
the differences between initiating and non-initiating pre-
scribers on the importance of factors like monitoring, 
patient compliance etc., while subtle, suggests response 
bias may be concealing the true depth of knowledge gaps.
Conclusions
The growth of NOACs is unsurprising and their avail-
ability generates choice for patients and prescribers. 
Nevertheless concerns persist: delays in the development 
of antidotes or reversal agents; medication adherence; 
higher cost of the NOACs compared to warfarin; lack 
of standardised and available tests to monitor/assess the 
level of anticoagulant activity; contraindications and drug 
interactions [22].
As a result, making the best NOAC prescribing deci-
sions, in such a complex environment with many influ-
ences, is challenging. While the factors influencing 
decisions may change over time as new and pragmatic 
evidence emerges, it is imperative that GPs prescribing 
NOACs are aware of and utilise the existing prescribing 
guidance so as to maximise the benefits and avoid the 
pitfalls of NOACs [23].
Limitations
While postal surveys are frequently used to collect infor-
mation from physicians, owing to their ease of use and 
relatively inexpensive nature we acknowledge that they 
are subject to limitations such as a low response rate and 
response bias [24–26]. Nevertheless the representative-
ness of the sample does appear to be in line with previous 
studies [16, 27] and OECD statistics [28].
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